A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax

BACKGROUND: Venetoclax (VEN) is the first selective small molecule Bcl-2 inhibitor approved by FDA and used in adult chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and some acute myeloid leukemia (AML). However, the long-term safety of VEN in large sample population was unknown...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yang, Shu, Yamin, Chen, Guosong, Yin, Yanchao, Li, Feie, Li, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728853/
https://www.ncbi.nlm.nih.gov/pubmed/36477747
http://dx.doi.org/10.1371/journal.pone.0278725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728853/
https://www.ncbi.nlm.nih.gov/pubmed/36477747
http://dx.doi.org/10.1371/journal.pone.0278725

Ejemplares similares